SGNLTKYWKKIWKPGIKKWIK
SGNLTKYWKKIWKPGIKKWIK is a thymidylate kinase (TMK)-targeting antimicrobial peptide with a KD value of 4.721 μM. SGNLTKYWKKIWKPGIKKWIK exerts antimicrobial effects through multiple mechanisms, including membrane disruption, induction of ROS, and DNA binding. SGNLTKYWKKIWKPGIKKWIK shows remarkable activity against Gram-negative bacteria, possesses good biocompatibility, and rarely induces drug resistance. SGNLTKYWKKIWKPGIKKWIK can be used for research on Gram-negative bacterial infections.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- 화학식: C128H200N32O26
- 분자량:2603.16
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
All DNA/RNA Synthesis Isoforms
More
Biological Activity
제품 설명
IC50 & Target
[1]|
IL-6 |
IL-1β |
In Vitro
SGNLTKYWKKIWKPGIKKWIK (2-128 μM; 12-18 h) potently inhibits the growth of Escherichia coli K88, with an MIC of 2 μM[1].
SGNLTKYWKKIWKPGIKKWIK (2 μM; 1 h) disrupts the membrane integrity of Escherichia coli K88, increases outer/inner membrane permeability, depolarizes the membrane[1].
SGNLTKYWKKIWKPGIKKWIK (1-64 μM; 2 h) induces reactive oxygen species production in Escherichia coli K88[1].
SGNLTKYWKKIWKPGIKKWIK (0-256 μM; 40 min) binds to the genomic DNA of Escherichia coli K88 and inhibits DNA migration[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:ICR mice (female, 6 weeks old, 20.00 ± 2 g, challenged with Escherichia coli K88 suspension)[1]
-
Dosage:20 mg/kg
-
Administration:i.p.; single dose
-
Result:Significantly reduced bacterial loads in liver, kidney, spleen, and lung.
Alleviated tissue damage (vacuolar degeneration of hepatocytes, renal tubular epithelial cell edema, granulocyte infiltration in spleen and lungs).
Reduced serum levels of proinflammatory cytokines (IL-6, IL-1β, TNF-α) and HMGB1.
Chemical Information
-
분자량 2603.16
-
화학식 C128H200N32O26
-
Sequence
Ser-Gly-Asn-Leu-Thr-Lys-Tyr-Trp-Lys-Lys-Ile-Trp-Lys-Pro-Gly-Ile-Lys-Lys-Trp-Ile-Lys
-
Sequence Shortening
SGNLTKYWKKIWKPGIKKWIK
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocol
-
Protocol for Electrophoretic Mobility Shift Assay (EMSA)
Electrophoretic mobility shift assay detects protein-nucleic acid binding by incubating a labeled DNA or RNA probe with purified protein or cell extract, then separating free probe from slower-migrating protein-probe complexes on a native gel. For cancer cells, primary neurons, mouse tumor samples, intestinal organoids, inflammatory macrophages, or drug-treated samples, EMSA can measure transcription-factor DNA binding or RNA-binding protein activity in extracts, but it does not directly measure transcription, protein expression, or chromatin occupancy in intact cells. Specificity is judged by competition with unlabeled wild-type probe, failure of mutated or unrelated competitors to compete, and antibody supershift or disruption when the binding protein identity must be confirmed.
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Gram Staining of Tissue Sections
Gram staining of tissue sections is a histochemical technique used to differentiate Gram-positive and Gram-negative bacteria within histological specimens based on differences in bacterial cell wall structure and dye retention, adapted from classical bacteriological Gram staining into tissue-compatible “histological Gram stain” variants. In tissue applications, modifications of the Brown-Hopps and Brown-Brenn methods are commonly used to improve differentiation of microorganisms embedded within host connective tissue and to reduce overstaining or loss of Gram-negative signal, which are known limitations of earlier approaches. The principle relies on crystal violet-iodine complex retention in Gram-positive organisms and subsequent decolorization and counterstaining steps that allow contrast visualization of Gram-negative organisms against tissue background.
순도&문서
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)